« Previous | Next » | All Messages |  CVBT Message Board Home | recommend post |  Ignore Poster

CVBT News CardioVascular BioTherapeutics Elects Dr. Thomas Stegmann Co-President

LAS VEGAS--(BUSINESS WIRE)--CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT), today announced that Thomas J. Stegmann, M.D., has been named co-president of the company. As co-founder and chief clinical officer, Dr. Stegmann pioneered the protein-based angiogenesis procedure upon which the company was founded. He will share leadership responsibilities with Daniel C. Montano, co-founder, who currently serves as president and CEO.

For the past 13 years, Dr. Stegmann’s research has focused on the field of neo-angiogenesis and human growth factors. He has spearheaded the use of FGF-1, a protein member of the fibroblast growth factor family, to stimulate the growth of cardiac blood vessels in patients with heart disease. His research has been published in peer-reviewed scientific journals, and he is the author of New Vessels for the Heart, the story of the effort he led to develop this protein for increasing blood vessel growth in the heart.

“Dr. Stegmann and I founded CardioVascular BioTherapeutics together in order to pursue the use of protein therapy as a treatment for cardiovascular disease, and we have worked hand-in-hand toward this goal from day one,” said Daniel C. Montano, president and CEO of CardioVascular BioTherapeutics, Inc. “As a leading researcher in this field, Dr. Stegmann is well-qualified to lead our company in our medical and scientific efforts while I focus on the business and financial aspects of the company.”

CardioVascular BioTherapeutics is focused on the development of protein-based drugs for the treatment of cardiovascular disease. The active ingredient in its drug candidates, Cardio Vascu-Grow^TM, contains a protein member of the fibroblast growth factor family designed to stimulate the growth of new blood vessels, also known as angiogenesis. The general principle is that once blood perfusion is increased in the affected areas, patients with cardiovascular disease may experience improvement in tissue repair and function.

“I am honored by this appointment and will continue to further the primary mission of the company, that being to present better treatment options for the patient,” said Dr. Stegmann. “Our long-term success as a company must be measured on the progress we make for patients, and I will lead CardioVascular BioTherapeutics’ efforts as we continue to conduct clinical trials in the U.S. and internationally with the goal of developing protein therapies to meet the needs of our patients suffering from cardiovascular disease.”

About CardioVascular BioTherapeutics

CVBT is a biopharmaceutical company developing drug candidates with Cardio Vascu-Grow™ as the active ingredient for a number of diseases characterized by inadequate blood flow to a tissue or organ. The company is currently conducting two FDA-authorized clinical trials: one in coronary artery disease in no-option heart patients, and one in impaired wound healing of the skin. Additionally, the company has completed pre-clinical studies in animal models of peripheral artery disease of the legs and stroke recovery. A foreign proof-of-concept clinical trial relating to chronic back pain believed to be caused by impaired or blocked lumbar arteries has been initiated.

Cardio Vascu-Grow^TM is a trademark of CardioVascular BioTherapeutics, Inc.

This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward-looking statements. Factors that might affect actual outcomes include, but are not limited to, results of future clinical and pre-clinical trials, differences in patient outcomes, FDA approval of CVBT drug candidates, market acceptance of CVBT products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage and financial performance. For a more detailed discussion of these and associated risks, see the company's most recent documents filed with the Securities and Exchange Commission.